SecBot SecBot
Biotech Drug Report Generated Nov 10, 2026

Ziihera

ZYME·Zymeworks Inc.
NEUTRAL
Drug Impact Rating4/10
Trial phase
Approved
Time to market
Already approved and marketed. First FDA approval was November 2024 (BTC), second was August 2026 (GEA).
Why 4/10
Ziihera is already FDA-approved in two indications (BTC in Nov 2024, GEA in Aug 2026) with no pending regulatory decision or hard dated binary catalyst in the next ~12 months. The next potential catalyst would be a regulatory filing for HER2+ colorectal cancer following the Aug 2026 Breakthrough Therapy Designation, but no PDUFA date has been set. As an approved, commercial-stage drug, the defining binary catalysts have passed.
Actionable Insight NEUTRAL

Ziihera is already approved in two indications (BTC and GEA) and generating royalty revenue through partners Jazz and BeOne. The next major catalyst would be a potential regulatory filing for HER2+ colorectal cancer following the August 2026 Breakthrough Therapy Designation, but no PDUFA date has been set. Watch for quarterly royalty revenue growth and any label expansion filings as the key value drivers.

Price Chart

Loading chart...

Executive Summary

Ziihera (zanidatamab) is a HER2-targeted bispecific antibody developed by Zymeworks Inc. (Nasdaq: ZYME) and commercialized by partners Jazz Pharmaceuticals and BeOne Medicines. It has received two FDA approvals: first in November 2024 for previously treated HER2-positive biliary tract cancer, and second in August 2026 for first-line HER2-positive advanced gastroesophageal adenocarcinoma (GEA), where Phase 3 data showed statistically significant overall survival improvement over the standard-of-care trastuzumab. Zymeworks has pivoted to a royalty-driven business model, collecting milestones and royalties from its partners, and raised 2026 revenue guidance to $337M-$351M after reporting Q3 revenue of $256.5M. The stock trades near its 52-week high with a Strong Buy analyst consensus and a mean price target of $41.50, implying ~40% upside.

How It Works

Ziihera is a bispecific antibody, meaning it is an engineered protein that can grab onto two different spots at once. It targets the HER2 protein, which is found in high amounts on the surface of certain cancer cells (like some breast, stomach, and bile duct cancers). Unlike standard HER2 antibodies such as Herceptin that bind to just one spot, Ziihera binds to two different spots on the HER2 protein simultaneously, which can lead to stronger cancer cell killing and better immune system engagement.

Trial Status

Ziihera is FDA-approved in two indications. The pivotal Phase 3 HERIZON-GEA-01 trial (first-line GEA) met its primary endpoint with statistically significant progression-free and overall survival benefits versus trastuzumab plus chemotherapy, with results published in the New England Journal of Medicine. Final results from the Phase 2 HERIZON-BTC-01 trial (biliary tract cancer) also showed durable responses. A Breakthrough Therapy Designation was granted in August 2026 for HER2-positive colorectal cancer, and Jazz is exploring trials in breast, colorectal, and lung cancers.

The Two-Sided Case

▲ Bull Case4
Ziihera is a first-in-class HER2-targeted bispecific antibody that binds two distinct HER2 epitopes, showing statistically significant overall survival benefit over trastuzumab in Phase 3 HERIZON-GEA-01 (median OS 26.4 vs 19.2 months), published in the New England Journal of Medicine.
The drug has secured two FDA approvals in under two years (BTC in Nov 2024, GEA in Aug 2026) and received Breakthrough Therapy Designation for HER2+ colorectal cancer in August 2026, opening a large addressable market.
Jazz Pharmaceuticals sees $3B-$5B peak sales potential for Ziihera, and Zymeworks has fortified its balance sheet with a $250M royalty-backed note from Royalty Pharma plus a $55M upfront from the Roche ZW209 deal.
Analyst consensus is Strong Buy (18 analysts: 7 Strong Buy, 11 Buy, 1 Hold) with a mean price target of $41.50, implying ~40% upside from the current ~$31 price. Q3 2026 revenue of $256.5M beat FactSet estimates of $227.4M.
▼ Bear Case4
Ziihera faces entrenched competition from trastuzumab (Herceptin), which has been the standard-of-care HER2 agent for over a decade in gastric cancer, and from Enhertu (trastuzumab deruxtecan) in later-line settings.
Zymeworks does not directly control Ziihera's commercialization; Jazz Pharmaceuticals and BeOne Medicines hold the marketing rights, so Zymeworks' revenue is limited to royalties and milestones, capping upside.
The Q3 2026 earnings release noted an EPS miss of -5% versus estimates, and the stock trades near its 52-week high, suggesting much of the good news may already be priced in.
Zymeworks' pivot to a royalty aggregation model adds execution risk from integrating acquired assets like Theravance Biopharma's YUPELRI, which may distract from pipeline progress.

Upcoming Catalysts

  • Potential regulatory filing for HER2+ colorectal cancer following August 2026 Breakthrough Therapy Designation (no PDUFA date set)
  • Quarterly royalty revenue reports from Jazz/BeOne Ziihera sales
  • Jazz Pharmaceuticals' ongoing/planned trials in breast, colorectal, and lung cancers
  • Zymeworks' own pipeline progress (ZW209 with Roche, ZW251 GPC3-targeting ADC)

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Zymeworks Inc. PRESS-RELEASE ZYME ·Originating report

Sources · 12

Hover a chip for the title
1 theglobeandmail.com2 fiercepharma.com3 theglobeandmail.com4 fox59.com5 morningstar.com6 morningstar.com7 fiercepharma.com8 nasdaq.com9 nejm.org10 marketscreener.com11 sec.gov12 sec.gov